Perampanel 6 MG
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Healthy
Conditions
Healthy
Trial Timeline
Oct 1, 2018 → Nov 29, 2021
NCT ID
NCT03653741About Perampanel 6 MG
Perampanel 6 MG is a approved stage product being developed by Eisai for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT03653741. Target conditions include Healthy.
What happened to similar drugs?
20 of 20 similar drugs in Healthy were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03653741 | Approved | Completed |
Competing Products
20 competing products in Healthy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 | AstraZeneca | Phase 1 | 29 |
| Valsartan | Novartis | Phase 1 | 29 |
| CSL112 + Placebo | CSL | Phase 1 | 29 |
| UT-15C | United Therapeutics | Phase 1 | 26 |
| VNA-318 + Placebo | Biotrial | Phase 1 | 19 |
| Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + Placebo | Trevena | Phase 1 | 19 |
| TRV130 + Moxifloxacin + Placebo | Trevena | Phase 1 | 19 |
| Radiolabeled TRV130 | Trevena | Phase 1 | 19 |
| TRV130A + Dextrose in Water | Trevena | Phase 1 | 19 |
| TRV734 | Trevena | Phase 1 | 19 |
| ALT02 + EU-licensed Herceptin + US-licensed Herceptin | Alteogen | Phase 1 | 29 |
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 29 |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 1 | 23 |
| MORF-057 + Placebo for MORF-057 | Eli Lilly | Phase 1 | 29 |
| Propranolol + Pseudoephedrine | Eli Lilly | Pre-clinical | 26 |
| LY2157299 | Eli Lilly | Phase 1 | 29 |
| Lasmiditan + Placebo | Eli Lilly | Phase 1 | 29 |
| LY3015014 + Placebo | Eli Lilly | Phase 1 | 29 |
| LOXO-783 | Eli Lilly | Phase 1 | 29 |
| LY2541546 - IV + LY2541546 - SC + Placebo | Eli Lilly | Phase 1 | 29 |